Covid Vaccine Race

The most common adverse event was myocarditis, which was reported in nearly 500 patients. None of those patients had died as of the new analysis, and the rate per million cases was 3.5 cases.

The full approval for BNT162b2 will afford physicians greater prescribing capability, and will likely drive workplace vaccine mandates.

The decision on the final federal approval in the US could mean many more people would get the vaccine.

The World Health Organization (WHO) announces the Solidarity PLUS platform trial of drugs repurposed to treat COVID-19 after Solidarity trial candidates disappoint.

The US federal government announces plans for mRNA COVID-19 vaccine booster doses, and more children and teens are getting hospitalized for the virus.

Common cloth and surgical masks allow for the build-up of aerosol droplets over time.

While an association was found, the adverse events are very rare.

All Americans who received either Pfizer or Moderna will be eligible 8 months after their second dose.

The Biden administration reportedly hopes for FDA-authorized booster doses for the adult general population in the next month.

The US is targeting a possible Fall rollout of publicly available doses, yet experts debate their current necessity.

Fewer than 10,000 adverse events among more than 8.9 million doses administered.

The Centers for Disease Control and Prevention (CDC) endorses the additional COVID-19 vaccine shot in immunocompromised people.

A quartet of infectious disease, vaccinology, and virology experts share thoughts on the FDA's newest emergency authorization for COVID-19 mRNA vaccines.

"Humans dislike change, especially when it is rapid, unexpected, or negative. Delta is all 3."

Donald Alcendor, PhD, shares expert perspective on the newest FDA authorization, as well as what a full COVID-19 vaccine approval would mean for US immunization.

The move will offer an extra boost of immunity for patients with compromised immune systems, including organ transplant recipients.

An England study shows the Pfizer-BioNTech and AstraZeneca vaccines remain effective in reducing symptomatic disease risk.

The Food and Drug Administration (FDA) is expected to expand the Emergency Use Authorization (EUA) of the Pfizer-BioNTech and Moderna vaccines for a third dose in those who might be vulnerable to COVID-19.

The vaccine demonstrated an acceptable safety profile in the adolescent population.

The federal agency recommends that all women who are pregnant, recently pregnant, and planning to become pregnant get the COVID-19 vaccine.

Emergency authorization may be complete before the end of August, ensuring more protection for patients burdened with certain chronic diseases.

Findings also showed that women had a lower risk of testing positive than men.

With the US federal government health agencies discussing plans for a booster dose for Americans and WHO’s call for a moratorium on these shots, a tale of two vaccine strategies is emerging.

The report of promising phase 2 findings align with word that an FDA submission will be delayed until later this year.

What risks and benefits need to be considered with the return of in-person classes?

As the international world struggles to get first doses, the World Health Organization Director General Tedros Adhanom Ghebreyesus says this should also include high-risk populations.

A report says the timetable is for Labor Day or sooner.

A study looked at the efficacy of the Pfizer-BioNTech mRNA COVID-19 vaccine in a high-risk national population within a real-world setting.

Ownership language showed an additional boost in appointment and vaccination rates.

The study found that ¾ of the cases occurred in fully vaccinated individuals.